Our Leadership Team

InSitu Biologics is an emerging biotech company focused on the development of AnestaGel™, a non-opiate painkiller. Meet the exceptional leaders that comprise our team:

Executive Team

Kevin Bassett MBA

Kevin Bassett, MBA

President & CEO

Kevin Bassett joined InSitu Biologics in September 2019 as President and CEO. Prior to joining InSitu, Mr. Bassett was General Manager of HLT Medical, a clinical-stage company developing a next-generation heart valve in the field of Transcatheter Aortic Valve Replacement (TAVR). Kevin has also served in a variety of senior executive roles in early-stage medical technology companies over the past 20 years.

Kevin is a certified public accountant (inactive license). He holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. in Accounting and English from St. John’s University. Kevin also held a commission as an officer in the United States Army Reserves from 1991 – 2001.

Bill Taylor

Bill Taylor

Chief Science Officer

Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, has been awarded over $900k in government research grants, and has authored industry papers in chemical remediation and demilitarization utilizing biological systems.

Bill holds a B.S. from the University of Minnesota with a double major in Chemical Engineering and Biology.

Kay Warnott, MSN

Vice President, Clinical Operations

Kay Warnott joined InSitu Biologics in December 2019 as Vice President of Clinical Operations. Kay is a graduate of University of Kentucky and has been a critical care nurse/acute care nurse practitioner for over 25 years. Kay began her pharmaceutical career in Clinical Research in 2003 as Director of Medical Affairs at the Medicines Company. Over the past 16 years, she has served in a variety of senior roles as Executive Director/Vice President Clinical Research and Operations with a demonstrated history of success in the pharmaceuticals industry.

Kay holds a Master of Science in Nursing (MSN)/Acute Care Nurse Practitioner focused in Acute Care, Critical Care, Cardiothoracic and Pulmonary Diseases and Pain Management. Kay has served on various physician advisory boards.

Kevin Barrett, MBA

Vice President, Operations/QA

Kevin Barrett joined InSitu Biologics in October 2019 as Vice President, Operations/ QA. Before joining InSitu, Kevin held Director positions in International and Program Management for Cardiovascular Systems Inc., a medical device company focused on developing and commercializing innovative solutions for treating coronary and peripheral artery disease. In addition, Kevin has served as Director of Operations for Angioslide Inc., a medical product company in the peripheral angioplasty space with a unique product that combines PTA balloon intervention with debris capture and removal.

Kevin holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. in Business from the University of Saint Thomas.

Board of Directors

James Knapp, CFP
Chairman

James saw the potential immediately and invested in InSitu Biologics in June of 2015.  James served as a director at InSitu Biologics from 2015 to 2018 and became Chairman of the Board in 2018.  He has 17 years of investment experience and holds a B.A. from Luther College in Management.  James is also President & CEO of Heritage Wealth Architects in Saint Paul, MN.

Dr. Robert Wilson, MD
Member

Dr. Wilson is an interventional cardiologist and Professor of Medicine who previously led the interventional cardiology program at the University of Minnesota.  He has extensive experience in medical device and business development. Dr. Wilson previously founded and led three medical device companies: Acist Medical Systems (diagnostic interventional cardiology equipment), HLT (transcatheter heart valve), and Egg Medical (radiation protection platform), where he is the Chief Executive Officer and Chairman.

Kevin Bassett, CEO
Member

Kevin Bassett joined InSitu Biologics in September 2019 as President and CEO. Prior to joining InSitu, Mr. Bassett was General Manager of HLT Medical, a clinical-stage company developing a next-generation heart valve in the field of Transcatheter Aortic Valve Replacement (TAVR). Kevin has also served in a variety of senior executive roles in early-stage medical technology companies over the past 20 years.